QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
NASDAQ:MRNA

Moderna Stock Forecast, Price & News

$71.31
+0.35 (+0.49 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$70.65
Now: $71.31
$73.10
50-Day Range
$54.34
MA: $68.09
$78.29
52-Week Range
$14.66
Now: $71.31
$95.21
Volume5.44 million shs
Average Volume16.89 million shs
Market Capitalization$28.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.45
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRNA
CUSIPN/A
CIKN/A
Phone617-714-6500
Employees975

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.21 million
Book Value$3.49 per share

Profitability

Net Income$-514,020,000.00
Net Margins-461.42%

Miscellaneous

Market Cap$28.14 billion
Next Earnings Date10/29/2020 (Confirmed)
OptionableOptionable
$71.31
+0.35 (+0.49 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Moderna (NASDAQ:MRNA) Frequently Asked Questions

How has Moderna's stock been impacted by COVID-19?

Moderna's stock was trading at $23.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MRNA shares have increased by 202.0% and is now trading at $71.31.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Moderna?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 1 sell rating, 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Moderna
.

When is Moderna's next earnings date?

Moderna is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Moderna
.

How can I listen to Moderna's earnings call?

Moderna will be holding an earnings conference call on Thursday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) released its earnings results on Wednesday, August, 5th. The company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.05. The firm had revenue of $66.35 million for the quarter, compared to analyst estimates of $24.24 million. Moderna had a negative net margin of 461.42% and a negative return on equity of 27.85%. Moderna's revenue for the quarter was up 407.2% on a year-over-year basis.
View Moderna's earnings history
.

What price target have analysts set for MRNA?

17 analysts have issued 12 month target prices for Moderna's shares. Their forecasts range from $24.00 to $134.00. On average, they anticipate Moderna's share price to reach $87.41 in the next year. This suggests a possible upside of 22.6% from the stock's current price.
View analysts' price targets for Moderna
.

Who are some of Moderna's key competitors?

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

Who are Moderna's key executives?

Moderna's management team includes the following people:
  • Dr. Noubar B. Afeyan Ph.D., Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board (Age 57, Pay $105k)
  • Mr. Stéphane Bancel, CEO & Director (Age 47, Pay $1.95M)
  • Dr. Stephen Hoge, Pres (Age 44, Pay $1M)
  • Dr. Tal Zaks, Chief Medical Officer (Age 54, Pay $832.43k)
  • Mr. Juan Andres, Chief Technical Operations & Quality Officer (Age 55, Pay $862.57k)

When did Moderna IPO?

(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

What is Moderna's stock symbol?

Moderna trades on the NASDAQ under the ticker symbol "MRNA."

Who are Moderna's major shareholders?

Moderna's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Ropes Wealth Advisors LLC (0.40%), Starr International Co. Inc. (0.02%), DNB Asset Management AS (0.01%), Pacer Advisors Inc. (0.01%), Nissay Asset Management Corp Japan ADV (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Moderna stock include Edwin M Kania Jr, Elizabeth G Nabel, Jennifer Ling Lee, Juan Andres, Lorence H Kim, Lori M Henderson, Paul Sagan, Peter Barton Hutt, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and Ventures Fund Iv Gene Flagship.
View institutional ownership trends for Moderna
.

Which institutional investors are selling Moderna stock?

MRNA stock was sold by a variety of institutional investors in the last quarter, including Ropes Wealth Advisors LLC, Moloney Securities Asset Management LLC, Evolution Wealth Advisors LLC, Professional Planning, Nisa Investment Advisors LLC, Larson Financial Group LLC, Harel Insurance Investments & Financial Services Ltd., and CWM LLC. Company insiders that have sold Moderna company stock in the last year include Edwin M Kania Jr, Elizabeth G Nabel, Jennifer Ling Lee, Juan Andres, Lorence H Kim, Lori M Henderson, Peter Barton Hutt, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Moderna
.

Which institutional investors are buying Moderna stock?

MRNA stock was purchased by a variety of institutional investors in the last quarter, including Starr International Co. Inc., Pacer Advisors Inc., Envestnet Asset Management Inc., Avantax Advisory Services Inc., Wedbush Securities Inc., Old Port Advisors, Carl P. Sherr & Co. LLC, and Avitas Wealth Management LLC.
View insider buying and selling activity for Moderna
.

How do I buy shares of Moderna?

Shares of MRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Moderna's stock price today?

One share of MRNA stock can currently be purchased for approximately $71.31.

How big of a company is Moderna?

Moderna has a market capitalization of $28.14 billion and generates $60.21 million in revenue each year. The company earns $-514,020,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Moderna employs 975 workers across the globe.

What is Moderna's official website?

The official website for Moderna is www.modernatx.com.

How can I contact Moderna?

Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-6500 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.